Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6). Several inhibitors, including compound <b>14</b> (BRD9757), exhibited excellent potency and selectivity despite the absence of a surface-binding motif. The binding of these highly efficient ligands for HDAC6 is rationalized via structure–activity relationships. These results demonstrate that high selectivity and potent inhibition of HDAC6 can be achieved through careful choice of linker element only
The phenothiazine system was identified as a favorable cap group for potent and selective histone de...
Herein, we report the discovery of a dual histone deacetylase inhibitor displaying a unique HDAC3/6 ...
Little is known about the biological and structural features that govern the isoform selectivity for...
Histone deacetylase 6 (HDAC6) is an established drug target for cancer treatment. Inhibitors of HDAC...
Non-selective inhibition of different histone deacetylase enzymes by hydroxamic acid-based drugs cau...
Histone deacetylase 6 (HDAC6) is unique hydrolase within HDAC family, having pleiotropic deacetylase...
Abstract: To find novel histone deacetylase 6 (HDAC6)-selective inhibitors and clarify the structura...
Histone deacetylase 6 (HDAC6) is unique hydrolase within HDAC family, having pleiotropic deacetylase...
Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective...
Histone Deacetylases are considered promising targets for cancer epigenetic therapy, and small molec...
Histone deacetylase 6 (HDAC6) is a crucial regulator in various cancer types and several non-oncolog...
The high structural homology of histone deacetylases 6 and 8 (HDAC6/8) poses a challenge in achievin...
Histone deacetylase 6 (HDAC6) is a crucial regulator in various cancer types and several non-oncolog...
Various diseases are related to epigenetic modifications. Histone deacetylases (HDACs) and histone a...
Histone deacetylases (HDACs) are known to deacetylate histones and other proteins, which makes HDAC ...
The phenothiazine system was identified as a favorable cap group for potent and selective histone de...
Herein, we report the discovery of a dual histone deacetylase inhibitor displaying a unique HDAC3/6 ...
Little is known about the biological and structural features that govern the isoform selectivity for...
Histone deacetylase 6 (HDAC6) is an established drug target for cancer treatment. Inhibitors of HDAC...
Non-selective inhibition of different histone deacetylase enzymes by hydroxamic acid-based drugs cau...
Histone deacetylase 6 (HDAC6) is unique hydrolase within HDAC family, having pleiotropic deacetylase...
Abstract: To find novel histone deacetylase 6 (HDAC6)-selective inhibitors and clarify the structura...
Histone deacetylase 6 (HDAC6) is unique hydrolase within HDAC family, having pleiotropic deacetylase...
Histone deacetylase 6 (HDAC6) is an attractive target for cancer therapeutic intervention. Selective...
Histone Deacetylases are considered promising targets for cancer epigenetic therapy, and small molec...
Histone deacetylase 6 (HDAC6) is a crucial regulator in various cancer types and several non-oncolog...
The high structural homology of histone deacetylases 6 and 8 (HDAC6/8) poses a challenge in achievin...
Histone deacetylase 6 (HDAC6) is a crucial regulator in various cancer types and several non-oncolog...
Various diseases are related to epigenetic modifications. Histone deacetylases (HDACs) and histone a...
Histone deacetylases (HDACs) are known to deacetylate histones and other proteins, which makes HDAC ...
The phenothiazine system was identified as a favorable cap group for potent and selective histone de...
Herein, we report the discovery of a dual histone deacetylase inhibitor displaying a unique HDAC3/6 ...
Little is known about the biological and structural features that govern the isoform selectivity for...